Icatibant

Icatibant is a Selective Competitive Antagonist at bradykinin type 2 receptor. it is a synthetic decapeptide with structure similar to bradykinin , but with 5-non-proteinogenic Amino Acids.it is mainly indicated for symptomatic treatment of acute attacks of hereditary Angioedema in adult with C- Esterase Inhibitor deficiency.

Brands
Adult Dose
Dose: 30 to 0 mg
Single Dose: 15 (15)
Frequency: 24 hourly
Route: SC
Instructions: Icatibant is injected Slowly due to volume to be administered is 3ml._x000D_if insufficiency , 2nd injection after 6hours, if needed, again after 6 hours, but not more than 3 in a period of 24hours.
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Decapeptide. It belongs to Bradykinin type II receptor Antagonist pharmacological group on the basis of mechanism of action.
Contraindications
Icatibant is contraindicated in conditions like Hypersensitivity to the drug.
Effects
The signs and symptoms that are produced after the acute overdosage of Icatibant include Hypotension, Erythema, itching.The symptomatic adverse reactions produced by Icatibant are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Rashes, Urticaria, Pruritus, Erythema, Pharyngitis, Cough, Asthenia, Nausea and vomiting, Nasal congestion, Hot flushes, Abnormal LFT, Pyrexia, Asthma, Proteinuria, Injection site reactions, dizziness, contusion, hereditary angioedema, increase blood creatinine phosphokinase, prolong prothrombin time, herpes zoster, increase Blood glucose, Abnormal LFT.
Indications
Icatibant is primarily indicated in conditions like Hereditary angioedema.
Interactions
No data regarding the interactions of Icatibant was found.
Interfrence
Risks
Drug should not be given to Paediatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Store Between 15°C-30°C. Refrigeration and Freezing is not recommended.
Warnings
Caution should be made while administering icatibant to patient with ischemic heart disease, stroke. First treatment should be given in a medical institution under guidance of physician. patients experiencing laryngeal attack should be observed after adminstration of icatibant at home. patients should be advised to not drive when feeling tired or dizzy
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.